On June 17, 2019, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. Though pembrolizumab is an established treatment option for non-small cell lung cancer, this is the first approval of pembrolizumab for small cell lung cancer. This approval was based on two clinical trials, KEYNOTE-158 and KEYNOTE-028, which measured tumor [...]
On May 17, 2019, The Centers for Medicare & Medicaid Services (CMS) released the final Medicare Part D Rule, where they decided to preserve the original Six Protected Classes policy. GO2 Foundation for Lung Cancer (formerly Lung Cancer Alliance and the Bonnie J. Addario Lung Cancer Foundation) advocated to stop the initial proposal that would have excluded certain drugs, including the Six Protected Classes from the Medicare Plan formularies. The Six Protected Classes policy was established over a decade ago to [...]
The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care”—individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for patients. We [...]
Each year, more than 1.8 million people receive a lung cancer diagnosis. Though research and treatment options have come a long way, there is still far more work to be done to stop the number one cancer killer. The Lung Cancer Registry was created for anyone who has been diagnosed with lung cancer to allow patients to be a part of the solution. The registry is a knowledge base for lung cancer researchers working to find medical treatments through data shared [...]
On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.
The landscape of cancer care is changing at a rapid pace with more research and treatment options than ever before. As exciting as these advancements are, the community standing by each cancer patient is equally important. Medical professionals, families, friends, advocates and organizations offering support services all play a crucial role in a survivor’s cancer journey. Our President and CEO, Laurie Fenton Ambrose, shared her perspective with The Washington Post on why community and partnerships are key to better cancer care. [...]
On March 18, the U.S. Food and Drug Administration approved a combination of the immunotherapy atezolizumab (Tecentriq) along with standard chemotherapy (carboplatin and etoposide) for patients who are starting treatment for extensive stage small cell lung cancer. This is the first immunotherapy approved up front, as a first treatment, for small cell lung cancer (SCLC). The approval was based on the IMPower133 clinical trial which showed that more patients survived longer when taking the combination than standard chemotherapy. Click here [...]
The LCA Science and Research team just returned from the 2019 Targeted Therapies of Lung Cancer Meeting, and we have good news: treatment options continue to expand in the targeted therapies and immunotherapy space to treat all types of lung cancer. Here’s what we learned. All of the advancements presented emphasize the importance of molecular testing/biomarker testing so that the best treatments can be chosen for a patient’s unique cancer. There are currently approved targeted therapies for patients whose cancers [...]